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In animals, the stimulation of pulmonary C fibres by the
injection of phenyl diguanide causes potent cardiovascular
and respiratory reflex effects such as hypotension,
bradycardia and apnoea followed by hyperventilation as
well as inhibitory viscerosomatic reflex effects on limb
motoneurones. These reflex changes occur in many
species including the cat whether it is decerebrate,
anaesthetised, or awake (Ginzel & Eldred, 1969, 1970;
Paintal, 1969, 1970, 1973; Deshpande & Devanandan,
1970; Schiemann & Schomburg, 1972; Kalia, 1973; Kalia
et al. 1973; Ginzel, 1973; Anand & Paintal, 1980; Pickar et
al. 1993).
In human subjects, the activation of these receptors by
intravenous or right atrial injections is associated with a
noxious sensation of respiratory discomfort in the throat
and chest (Bevan & Murray, 1963; Jain et al. 1972; Raj et
al. 1995; Gandevia et al. 1998b; for review see Paintal,
1986, 1995). The duration of the sensation is dose
dependent but, in conscious human subjects, there was no
evidence for the viscerosomatic reflex inhibition of limb
motoneurones which is present in animals (Gandevia et al.
1998b). In the study by Gandevia et al. (1998b), two distinct
types of sensations were reported, the early noxious
sensation and the subsequent sensation of ‘breathlessness’
or ‘air hunger’. It was assumed that the time course of the
noxious sensations evoked by the injection of lobeline
indicated the time course of pulmonary C fibre stimulation.
Doses of lobeline between 40 and 70 µg (kg body weight)_1
gave sensations lasting about 30 s.
The relatively short latency for the early sensation (~10 s
in response to lobeline delivered to the right antecubital
vein) does suggest that the noxious sensations are
initiated by the activation of pulmonary afferents rather
than receptors in the systemic circulation (Jain et al.
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1. The sensations evoked by the injection of lobeline into the right antecubital vein were studied
in 8 subjects after bilateral lung transplantation and 10 control subjects. In control subjects,
two distinct sensations were experienced. There was an early noxious sensation (onset ~10 s)
followed by a late sensation of breathlessness (onset ~26 s) associated with involuntary
hyperventilation. The early sensation was accompanied by respiratory and cardiovascular
changes.
2. In contrast to control subjects, the early respiratory events and the noxious sensations evoked
by injections of lobeline (18–60 µg kg_1) did not occur in subjects with recent bilateral lung
transplantation. This suggests that the early respiratory sensations are mediated by the
discharge of receptors in the lungs.
3. The late hyperventilation and the accompanying sensation of breathlessness occurred in both
transplant and control subjects and are therefore likely to be mediated by receptors elsewhere
in the body, presumably systemic arterial chemoreceptors stimulated by lobeline.
4. In control subjects, but not transplant subjects, there was a consistent decrease in mean arterial
pressure associated with the lobeline injection. This suggests that pulmonary afferents mediate
the hypotension.
5. For transplant subjects studied more than a year after transplantation, there was some
evidence that the noxious respiratory sensations evoked by lobeline had returned. This
suggests that some functional reinnervation of pulmonary afferents may occur.
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1972; Raj et al. 1995; Gandevia et al. 1998b). However,
the duration of the noxious sensations at the doses used in
our study (~30 s) was sufficiently long for systemic
circulation of the lobeline. Therefore, to determine
whether the extended noxious sensations associated with
these injections of lobeline were evoked by non-pulmonary
afferents, we studied subjects with complete pulmonary
denervation.
The respiratory sensations along with the cardiovascular
and respiratory changes associated with intravenous
injections of lobeline were assessed in control subjects and
in subjects after bilateral lung transplantation. We
compared three aspects of the responses to lobeline in
the control and transplant subjects: (i) the early noxious
sensation and associated respiratory events such as
coughing and apnoea, (ii) the later sensation of
‘breathlessness’ and the associated hyperventilation, and
(iii) changes in mean arterial pressure and heart rate. This
allowed us to examine which of the responses to lobeline
injection can be attributed to pulmonary afferents and
which are mediated by stimulation of other receptors.
Some of the results have been presented in an abstract
(Gandevia et al. 1998a).
METHODS
Studies were conducted on 8 subjects (5 males and 3 females, aged
20–52 years) who had received bilateral lung transplants (4 of these
had undergone bilateral lung and heart transplantation), and
2 subjects who had undergone heart transplantation alone (2 males,
aged 56 and 65 years). The majority (7 out of 8) of these subjects had
been transplant recipients in the previous 13 months or less so the
chance of reinnervation of the lungs was considered to be small
(Higenbottam et al. 1989; Hathaway et al. 1993; Seals et al. 1993;
Iber et al. 1995; Ramaekers et al. 1996). All transplant subjects were
clinically well at the time of the study but were on a regimen of
immunosuppression and antimicrobial medications. For the heart
and lung recipients (n = 4) the trachea was divided 1 cm above the
carina. For the bilateral lung recipients (n = 4), the main bronchi
were sectioned just distal to their bifurcation. We also studied
10 control subjects (5 female and 5 male, aged 26–46 years) who were
healthy and had no history of significant respiratory or neurological
illness. The heights of the transplant and control subjects
respectively ranged from 157 to 179 cm (mean ± S.E.M., 169 ± 3 cm)
and 157 to 192 cm (mean, 172 ± 3 cm) and their weights ranged from
43 to 75 kg (mean, 66 ± 6 kg) and from 55 to 80 kg (mean, 68 ± 3 kg).
Subjects were comfortably seated for all procedures. Informed
written consent was obtained from the subjects and the procedures
were approved by the local ethics committee and conformed to the
Declaration of Helsinki.
Lobeline and saline injections
A cannula was inserted in the antecubital vein at the right elbow and
extension tubing connected (1.1 ml deadspace) so that injections
could be made remotely. Subjects were unaware of the timing of the
injections. The lobeline HCl (Clinalfa, Switzerland) was prepared in
saline at a concentration of 1 mg ml_1. Injections of either saline or
lobeline (3 different doses) were delivered in a pseudo-random order
to each subject. The lobeline was always given in increasing doses but
these injections were randomly interspersed with an injection of
saline as a control. The deadspace of the tubing was primed with the
appropriate solution in advance of injection without the subject’s
knowledge. The timing and duration of injections were marked using
a switch activated by an experimenter. Latencies were measured
from the onset of injections. Instructions to subjects were read from
a prepared script and all extraneous visual and auditory stimuli were
minimised to ensure that the level of attention was similar for each
injection and for each subject (see Gandevia et al. 1998b).
The doses of lobeline ranged from 18 to 60 µg kg_1. In a previous
study, using identical procedures, we determined the threshold dose
for respiratory sensations in healthy controls to be ~18 µg kg_1 and
the threshold dose for evoking cough to be ~36 µg kg_1 (Gandevia et
al. 1998b). Subjects usually received three different doses of lobeline
of ~20, 40 and 60 µg kg_1 (termed low (< 25 µg kg_1), intermediate
(30–45 µg kg_1) and high (52–60 µg kg_1) doses (see Table 1).
Intervals of 5–10 min separated injections and up to three to five
injections of lobeline were performed in a session. All control subjects
(n = 10) received low, intermediate and high doses, while for
transplant subjects 5 of 8 received low doses, all 8 received
intermediate doses and 6 of 8 received high doses (see Table 1 and
Fig. 3).
A Doppler method was used to estimate the transit time for an
injected solution to reach the right atrium from the injection site at
the elbow (Michenfelder et al. 1972). The right atrium was targeted
with a dual-frequency ultrasound probe positioned parasternally in
the right third intercostal space (Parks Medical Electronics, model
915-AC, Aloha, OR, USA). A characteristic change in the auditory
signal occurred shortly after injection of a mixture of 1–3 ml of saline
with fine microbubbles. This occurred at 2.3–3.5 s following injection
in both control and transplant subjects (mean 3 s).
Measurements of responses to lobeline injection
To determine the onset and intensity of any sensations associated
with breathing, each subject signalled with a rotary potentiometer
operated by the left hand. In some studies, the onset of other
sensations associated with the injections (such as hot flushes or
nausea) were signalled by an additional transient movement of the
potentiometer. At least 2 min after each injection the subject was
asked to describe any respiratory sensations and the responses were
transcribed from tape recording. The subject then selected evoked
sensations from a list (based on sensations reported by Raj et al. 1995;
as used by Gandevia et al. 1998b) and indicated their apparent
location (nose, throat, larynx, upper or lower chest, or elsewhere).
The listed sensations (in order) included: (1) ‘air hunger’, (2) ‘tightness
in the chest or elsewhere’, (3) ‘difficulty or discomfort with
breathing’, (4) ‘choking’, (5) ‘wheezing’, (6) ‘pain or burning in the
chest or elsewhere’, (7) ‘swallowing’, (8) ‘smoke in the throat’, (9) ‘a
need to cough’, and (10) ‘any other sensations’. To estimate the peak
intensity of respiratory discomfort for each selected sensation,
subjects selected a number from a modified 10-point category scale
(Borg, 1982) as used in other studies of respiratory discomfort
(e.g. Gandevia et al. 1993, see Fig. 3 legend).
We monitored blood pressure, heart rate and ventilation. Blood
pressure was measured continuously using a plethysmograph-based
system from a finger of the right hand (Ohmeda 2300, Finapres, WI,
USA). Ventilation was measured non-invasively with a pair of
calibrated inductance bands positioned around the upper chest and
abdomen. The gains of the signals were adjusted using the isovolume
manoeuvre (Chadha et al. 1982). In addition, oxygen saturation was
measured with an oximeter which also provided heart rate (averaged
over 5 beats). End-tidal levels of CO2 were monitored via nasal prongs
(Ametek, Pittsburgh, PA, USA). All signals were recorded on tape
(Vetter PCM) and simultaneously sampled at 100 Hz and stored to
disk (Cambridge Electronic Design 1401+, Spike 2, Cambridge, UK)
for subsequent analysis.
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Analysis of sensations
For the sensory responses, the latency of the onset of any sensations
after the start of the injection and their time course were derived
from the potentiometer signal and were measured with cursors. Peak
intensity of each sensation was taken from the subjective response
reported on the 10 point Borg scale. The sensory descriptors were
divided into two categories: (i) those related to a noxious sensation in
the chest or throat (sensations labelled 6, 8 and 9, see above under
‘Measurement of responses to lobeline injection’) and (ii) those related
to breathlessness or ‘air hunger’ (sensations labelled 1, 2 and 3, see
above). This allowed a comparison of the two distinct types of
sensation. The Borg score for each sensation within each of the two
subgroups was then summed to give total scores – the higher the
score, the more severe the sensations related to the lobeline injection
(maximum possible score = 30).
Sensations 4, 5 and 7 were not formally included in the analysis.
Sensation 5 was not reported by any subject. Sensations 4 and 7 were
only ever reported by control subjects. They were not included since
a sensation of ‘choking’ could be related to breathlessness as well as
respiratory discomfort, and the presence of ‘swallowing’ was not
always accurately reported by the subjects.
Analysis of cardiorespiratory variables
Changes in heart rate were assessed from the signal of heart rate
averaged over five beats. Blood pressure changes were assessed on a
beat-to-beat basis. Mean arterial pressure (MAP) was calculated
from systolic and diastolic pressures with a standard formula
(1/3(systolic _ diastolic) + diastolic). Minute ventilation was
calculated on a breath-by-breath basis from the calibrated chest and
abdominal inductance bands and hyperventilation was defined by a
decrease in end-tidal CO2.
Average heart rate, systolic, diastolic and mean arterial pressures,
and minute ventilation were measured before the onset of the
injection. The onset time of changes in these variables was
determined using cursors. For heart rate and blood pressure, the
amplitude of any changes was measured. The average level of
ventilation between ~20 and 60 s after the injection was expressed
relative to the average level before the injection.
An early respiratory event was defined as the occurrence of
hypopnoea, apnoea or a cough at the same time that the subject
signalled the onset of sensations.
Statistical analyses
All key comparisons were made using non-parametric statistical
tests. Spearman’s rank correlation was used to relate the timing and
intensity of the sensations to all delivered doses of lobeline. A 2-way
analysis of variance (ANOVA) on ranks was used to assess the
differences in Borg score for the sensory variables. If a significant
difference was detected between control and transplant subjects a
Mann-Whitney U test was used to determine at which doses the
difference occurred. Fisher’s exact tests were used to compare the
number of subjects in each group that experienced lobeline-related
sensations, or had changes in cardiovascular and respiratory
variables. Statistical significance was set at the 5 % level. Significant
changes in MAP were defined by a change outside twice the
interquartile range of the pre-injection values. Unless otherwise
stated, data are given as median and interquartile ranges (IQ range).
All statistical analyses (except regression) were performed on one
value per subject for each dose. Responses were averaged if subjects
received more than one injection at the same dose. The linear
regression and mean (± S.E.M.) are used for illustrative purposes only
in parts of Fig. 2.
RESULTS
Sensory responses
In contrast to subjects with bilateral lung transplants, all
control subjects (n = 10) reported a noxious sensation in
the throat, larynx and upper chest. Most control subjects
(8 of 10) also reported a later sensation of breathlessness
following injections of lobeline (Figs 1A, 2A and 3). Both
the noxious sensation and the sensation of breathlessness
increased in intensity with increasing dose of lobeline
(Spearman’s rank correlation; each P < 0.05). There were
no false positive reports of respiratory sensations in any
subject when saline had been injected or when no injection
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Table 1. Subject data
Time since
Subject Transplant operation Prior disease Lobeline doses
(months) (µg kg_1)
1M BLT 0.5 Bronchiectasis 20, 40, 60
2M HLT 0.5 (and 31) Ventricular septal defect 20, 40, 60
1F BLT 3 Bullous emphysema 30, 60
2F HLT 4 Post-partum hypertension 30, 60
3M BLT 5 Emphysema 18, 30, 42
4M BLT 12 Cystic fibrosis 20, 40, 60
3F HLT 13 Bronchiectasis 30, 43, 52, 60
5M HLT 90 Sarcoidosis 20, 20, 40, 40
6M HT 2 Cardiomyopathy 20, 40, 40, 60
7M HT 2.5 Cardiac failure 20, 40, 60, 80
Controls
(n = 10) — — — 20, 40, 60
Subject data for control subjects (bottom line) and individual subjects with bilateral lung transplants
(BLT), heart and bilateral lung transplants (HLT) and heart transplants alone (HT). Male subjects are
indicated by ‘M’ and female subjects by ‘F’. Data include time since transplant operation, prior disease and
lobeline doses delivered in the study. 
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had occurred. As noted previously in control subjects
(Gandevia et al. 1998b), the higher the dose of lobeline,
the longer the duration of respiratory discomfort and the
shorter the onset latency of sensations (each P < 0.05)
(Fig. 2B and C, left panels). However, in the subjects with
bilateral lung transplants, there was no correlation
between the dose of lobeline and the onset time of sensation
(P = 0.3) or the duration of the evoked sensations
(P = 0.5) (Fig. 2B and C, right panels).
The full range of sensations and their intensities are
shown for all subjects and doses in Fig. 3. The sensations
are ordered such that they are divided into subgroups
(noxious sensations on the left and sensations of
breathlessness on the right). In this figure, the larger the
size of each symbol the higher the intensity of the
sensation. It suggests that the occurrence and intensity of
the sensations evoked by injection of lobeline were
greater in control subjects compared with transplant
subjects at all doses. The formal analysis is depicted in
Fig. 4 for the initial noxious sensation, the sensation of
breathlessness and the respiratory effects of the ‘stimuli’.
At the three doses, the intensity of the noxious sensations
was significantly greater in control than transplant
subjects (ANOVA on ranks, P < 0.001). The tendency for
sensations of breathlessness to have a higher intensity
rating in control subjects was not statistically significant
for each dose. For the transplant subjects there was only
a weak positive correlation between dose and sensations
related to breathlessness or ‘air hunger’ (P < 0.05) but no
correlation between dose and the noxious sensation in the
chest and throat (P = 0.2). Both control and transplant
subjects localised the sensations to the throat, upper and
lower chest while only control subjects reported
sensations in the nose, mouth and larynx.
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Figure 1. Responses to injection of lobeline in a control and a transplant subject
Typical examples of responses to injections of the intermediate dose of lobeline HCl (40 µg kg_1) from a
control subject (A) and a subject with a bilateral lung transplant (B, subject 1M in Table 1). Top trace shows
the timing of the injection and any swallow or cough. Second trace is from the potentiometer used to
signal sensations associated with the injection of lobeline. The earliest sensations were the noxious
sensations (e.g. A, ‘smoke in the throat’). The control subject also showed a brief apnoea. Both subjects
signalled a sensation of ‘air hunger’ which was accompanied by a period of hyperventilation. The
hyperventilation resulted in a reduction of the end-tidal CO2 (bottom trace). Changes in heart rate (HR
(bpm, beats min_1)) and blood pressure (BP) are also evident in each subject. 
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Cardiorespiratory responses
In addition to the sensory changes, lobeline changed
ventilation, blood pressure and heart rate. For control
subjects, an early respiratory ‘event’ (defined as a cough
or apnoea, see Methods) occurred in all subjects for the
intermediate (6 apnoeas, 4 coughs) and high doses
(3 apnoeas, 7 coughs) of lobeline. At these doses only one
of 8 transplant subjects studied at the intermediate dose
(cough) and 3 of 6 transplant subjects studied at the high
dose had early respiratory events (2 apnoeas, 1 cough), a
significant difference between the groups (Fisher’s exact
test, P < 0.05 for both doses; Fig. 4C). The brief apnoea or
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Figure 2. Effect of different strength doses on the onset time and duration of evoked sensations
A, incidence of evoked sensations to different doses of lobeline (low, intermediate and high) in control
subjects (left panel) and lung transplant subjects (right panel). Both noxious sensations and sensations of
breathlessness are included. Each subject is represented once for each dose. B, onset latency of first evoked
sensations plotted against the dose of lobeline (µg kg_1) for all subjects at all injected doses (some subjects
are represented more than once at the same or similar doses). For control subjects (left panel) there is a
significant negative correlation between onset of sensations and dose of lobeline (P < 0.05), while for the
transplant subjects (right panel) there is not (P = 0.3). C, duration of evoked sensations plotted against the
dose of lobeline for all subjects. For control subjects (left panel) there is a significant positive correlation
between duration of sensation and dose of lobeline (P < 0.05), while for the transplant subjects (right
panel) there is not (P = 0.5). Occasionally some doses of lobeline produced sensations lasting less than 1 s
and the relevant points appear close to zero in the panel. Lines represent the significant linear
correlations. Note that some subjects did not signal sensations at some doses. These data are represented
in the graphs in C as points at time zero but are not included in the statistical analyses of correlations. 
) by guest on April 20, 2011jp.physoc.orgDownloaded from J Physiol (
hypopnoea usually lasted about 2–4 s and in control
subjects was usually associated with a swallowing
movement. The timing of the early respiratory events
commonly coincided with the onset of induced sensations.
In the majority of control and transplant subjects, a long-
latency hyperventilation occurred in response to injections
of lobeline (Fig. 4D). This is likely to reflect the stimulation
of remote arterial chemoreceptors by systemic circulation
of the lobeline. The hyperventilation was accompanied by
a sensation of breathlessness in most subjects (Fig. 4B).
On average, ventilation increased 2- to 3-fold compared
with the pre-injection level in both control and transplant
subjects with the intermediate and high doses of lobeline.
There was no difference in magnitude between subject
groups (P = 0.5). At high doses the ventilatory increases
occurred at 25 s (IQ range 20–27 s) for control subjects and
at 16 s (14–20 s) for transplant subjects (P = 0.14).
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Figure 3. Individual reports of sensation type and intensity for each dose
Representation of reports from individual subjects of sensation in response to low, intermediate and high
doses of lobeline. For transplant subjects (three top panels), time since lung transplantation (months) and
type of transplant (BLT or HLT) are indicated (at left). Transplant subjects are ranked from shortest to
longest time since transplantation from the top to the bottom row. Data from control subjects are shown
in the three bottom panels. Sensation descriptors are labelled along the bottom and are divided into
noxious sensations (left column), sensations of breathlessness (right column) and other sensations (middle
column). The size of each octagon represents the intensity of the sensation as reported by each subject on
the 10 point Borg scale. There are 5 sizes of octagon representing Borg score ranges. The octagons from
smallest to largest represent scores of 0.5 and 1; 1.5, 2 and 2.5; 3, 3.5 and 4; 4.5, 5 and 5.5; and 6, 6.5, 7
and 8 respectively (see below), and thus the larger the octagon the more intense the sensation. Blank
spaces represent no sensation. Dashed lines represent subjects not studied at that dose. One representative
injection per subject for each dose is shown. 
Borg score descriptors: 10     Extremely large (max.) 4     Considerable
9 3     Moderate
8 2     Mild
7     Very large 1     Slight
6 0.5  Just noticeable
5     Large 0     Infinitely small
) by guest on April 20, 2011jp.physoc.orgDownloaded from J Physiol (
Ventilation returned to pre-injection level about 1–2 min
after the hyperventilation began (see Fig. 1A).
In response to injections of lobeline, we observed a
significant decrease in blood pressure beginning at about
12–15 s in all control subjects. The mean arterial pressure
decreased after injection of lobeline for the intermediate
dose (by 23 mmHg; 17–27 mmHg (median; IQ range))
and for the high dose (by 30 mmHg; 22–42 mmHg). By
contrast, two of the six transplant subjects showed a
significant decrease in mean arterial pressure after
injection of lobeline at the high dose and this incidence is
significantly less than in control subjects (P < 0.05;
Fig. 5A). One transplant subject showed a small increase
in MAP in response to lobeline injections.
The changes in heart rate after lobeline injection were
complex and no clear patterns emerged (Fig. 5B). At
the intermediate dose, heart rate increased by
10–33 beats min_1 (median increase 22 beats min_1) in
eight control subjects with a latency of 15–30 s and by
5–13 beats min_1 (median increase 9 beats min_1) in two
transplant subjects. Heart rate decreased in two control
subjects (by 7 and 9 beats min_1) and in two transplant
subjects (by 7 and 30 beats min_1). There was no significant
difference in the cardiovascular responses to lobeline
injection between subjects with bilateral lung transplants
and those with both heart and bilateral lung transplants.
However, the small numbers may mask subtle differences.
Responses to lobeline in subjects with heart
transplant alone
The responses to lobeline injections were also tested in
two subjects who had undergone heart transplants alone.
These subjects were on a similar regimen of immuno-
suppression and antimicrobial medications and were
viewed as a ‘patient’ control group for this reason. The
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Figure 4. Intensity of evoked sensations and incidence of respiratory responses associated with
different doses of lobeline
Intensity of evoked sensations (A and B, mean ± S.E.M.) and incidence of corresponding respiratory
responses (C and D) associated with low, intermediate and high doses of lobeline. 5, data from transplant
subjects; 4, data from control subjects. There was a significantly higher intensity of noxious sensation
and a higher incidence of early respiratory events experienced by the control subjects at all doses (A and
C). There was no significant difference between control and transplant subjects in the intensity of the
breathless sensation or in the incidence of hyperventilation (B and D). Note that the intensity of the two
types of respiratory sensation is expressed as the sum of three Borg ratings and the maximal possible score
is 30 (see Methods). * Significant difference between groups (P < 0.05). One value per subject for each dose
was used in the analysis. 
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sensations produced by lobeline injection in these subjects
were similar to those in control subjects. The subjects
reported sensations of breathlessness (Borg score for each
subject, 5 and 2.5) and noxious sensations (Borg score, 6.5
and 2.5) localised to the throat, upper and lower chest.
Both heart transplant subjects showed a decrease in blood
pressure in response to lobeline. One of these subjects
coughed, hyperventilated and increased heart rate after
injections.
Results in subjects with long-term bilateral lung
transplants
Up to this point, data from all lung transplantation
subjects have been considered together. However, at
intermediate doses, noxious sensations after the injection
of lobeline were experienced by three of the lung
transplant subjects. These three subjects were all studied
12 months or more after transplantation. At the high
dose, a noxious sensation was also experienced by one
other bilateral lung transplant subject studied only
3 months post-transplantation. One possible explanation
is that afferent reinnervation of the lungs may occur. To
investigate this possibility, one subject who was studied
2 weeks post heart and bilateral lung transplantation and
who had not reported any sensations in response to
lobeline injections was tested 31 months post-transplant
using similar procedures. In contrast to the initial study,
in the second study the subject reported sensations
associated with the intermediate and high doses of
lobeline. At the high dose (60 µg kg_1) he signalled a
noxious sensation (at 12 s) and breathlessness (at 26 s) and
experienced marked hyperventilation (Fig. 6). The
noxious sensation consisted of ‘choking in the throat’ and
‘a need to cough’ (Borg score = 3 for each). The subject also
experienced breathlessness including ‘tightness localised
to both the chest and the throat’, ‘difficulty with
breathing’ and ‘air hunger’ (Borg score = 6 for each). The
total duration of lobeline-induced sensations was 71 s.
Other sensations
Subjects also reported other sensations associated with the injection
of lobeline. These occurred after the initial noxious sensations. They
included nausea and hot flushes of the face, neck and shoulders. Five
of ten control subjects and one transplant subject reported nausea
(P = 0.3). Five of ten control subjects and six of eight transplant
subjects reported a hot flush after the injection of lobeline (P = 0.4).
DISCUSSION
This study shows definitively that receptors in the
human lungs are activated by suprathreshold doses of
lobeline and this leads to noxious respiratory sensations.
In recent lung transplant subjects no noxious respiratory
sensations were reported after lobeline injections. In
transplant subjects studied 12 months or more post-
transplantation some noxious sensations were reported
although of less intensity than in the control subjects.
This study also suggests that after 1–2 years there may
be functional reinnervation of the lungs after complete
denervation associated with bilateral lung transplantation.
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Figure 5. Incidence of cardiovascular changes associated with different doses of lobeline
Incidence of changes in mean arterial pressure (MAP; A) and heart rate (HR, B) with low, intermediate
and high doses of lobeline. Graphs depict increases (upwards columns) and decreases (downwards columns)
in MAP and heart rate. 4, data from control subjects; 5, data from transplant subjects. There was a
significantly higher incidence of decreased MAP in the control subjects at the intermediate and high doses
of lobeline. * Significant difference between groups (P < 0.05). The incidence of heart rate changes and
their direction did not differ between control and transplant subjects. One value per subject for each dose
was used in the analysis. ) by guest on April 20, 2011jp.physoc.orgDownloaded from J Physiol (
There have been many investigations into the mechanism
of the sensations and cough in response to lobeline
injection in humans. Lobeline was commonly used in
patients to assess circulation time on the basis of the time
it took for subjects to experience cough and hyper-
ventilation after injection (Robb & Weiss, 1934; Berliner,
1940; Bevan & Murray, 1963; Stern et al. 1966). The
receptors which caused the cough in humans were first
believed to be in the systemic circulation but were later
localised to an area supplied by the pulmonary circulation
(Eckenhoff & Comroe, 1951; Bruderman et al. 1966; Stern
et al. 1966; see also Dawes et al. 1951). Injections of
lobeline into the left chambers of the heart in humans do
not cause cough but can cause hyperventilation, whereas
injections into the descending aorta cause no changes in
ventilation (Stern et al. 1966). However, the sensations
experienced by patients after injections of lobeline were
initially postulated to be caused by stimulation of
receptors in the pleura or in the bronchi (Eckenhoff &
Comroe, 1951). More recently, Raj et al. (1995) tested the
threshold for sensations resulting from injections of
lobeline in human subjects. They suggested that the
afferents responsible for the noxious sensations were
pulmonary C fibres as the threshold for sensation did not
change after sensitisation of rapidly adapting pulmonary
receptors. Our study strongly supports a role for
pulmonary afferents which are accessible to the
pulmonary circulation in the production of short-latency
noxious respiratory sensations such as burning or smoke
in the chest and throat, and a need to cough. The data
suggest that the full duration of the sustained noxious
sensation requires intact pulmonary vagi. Although most
lung transplant subjects reported sensations of
‘breathlessness’ at the same intensity as control subjects,
only half ever reported noxious sensations although at a
lower intensity and at a higher threshold than control
subjects. We suggest that some pulmonary reinnervation
may account for the low intensity noxious sensations
experienced by these subjects. Consistent with this, when
one transplant subject who had initially felt no sensations
was studied 2.5 years later, typical sensations associated
with pulmonary C fibre stimulation by lobeline had
returned. While there has previously been little evidence
for reinnervation in human lung transplant recipients
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Figure 6. Two studies in one transplant subject
Data from a heart and bilateral lung transplant subject studied at 2 weeks (A) and 2.6 years after the
transplantation (B) (subject 2M in Table 1). Top traces show the timing of the injections. Second trace is
from the potentiometer used to signal sensations associated with the injection of lobeline. The subject
signalled no sensations on the first occasion but signalled both noxious sensations and sensations of
breathlessness in response to the same dose (60 µg kg_1) of lobeline 2.6 years after the surgery. Sensations
of air hunger were associated with a period of hyperventilation as indicated by the increased respiratory
movement (fifth trace) and the subsequent decrease in end-tidal CO2 (sixth trace). ) by guest on April 20, 2011jp.physoc.orgDownloaded from J Physiol (
prior to 12 months post-transplantation (Higenbottam et
al. 1989; Hathaway et al. 1993; Iber et al. 1995;
cf. Ramaekers et al. 1996), pulmonary reinnervation has
been reported after about 8 months in allograft
transplanted rats (Kawaguchi et al. 1998), 5 months in
autotransplanted dogs (Mattila et al. 1987) and 2 months
in autotransplanted monkeys (Mihm et al. 1989).
Membrane receptors sensitive to lobeline have been
reported in experimental neuromas (Leah et al. 1988), but
in those transplant subjects who felt noxious sensations,
the latency after lobeline injection suggests that the
receptors were accessible to the pulmonary circulation.
Alternatively, it is possible that recovery of sensitivity to
lobeline may have occurred through changes in intact
pathways over time. Sensitivity of non-pulmonary
receptors may have increased or plastic changes may have
occurred in the CNS (e.g. Pan et al. 1998). Changes secondary
to altered pulmonary perfusion following angiogenesis
may also be relevant. 
The intensity of the breathless sensation and the
incidence of hyperventilation in response to lobeline
injection were not significantly different between control
and transplant subjects. This suggests that receptors
which cause the hyperventilation are located neither in
the lungs nor the heart, but elsewhere in the systemic
circulation such as in the carotid body. Overall, based on
the apparent dissociation of the noxious sensations and
the sensations of breathlessness in the transplant
subjects, our results suggest that the noxious sensations
are due to the stimulation of pulmonary afferents (most
likely to be pulmonary C fibres) whereas the sensations of
breathlessness probably depend on the activation of
arterial chemoreceptors.
Although heart rate changes were variable across
subjects, there was a consistent decrease in mean arterial
pressure in control subjects in response to the injection of
lobeline that was not consistent across transplant subjects.
From these data, we suggest that the lobeline-induced
decrease in mean arterial pressure is a reflex response to
the stimulation of pulmonary afferents.
The cardiovascular changes associated with injections of
lobeline in human subjects have been observed during the
early period of ventilatory depression or apnoea (Bevan &
Murray, 1963). However, blood pressure and heart rate
changes have not always been observed in humans
probably because of the dosage delivered (Jain et al. 1972;
Raj et al. 1995). In contrast to lobeline, phenyldiguanide
causes no noxious sensations in human subjects but does
cause reflex hypotension, bradycardia and hyper-
ventilation, presumably by stimulation of carotid body
chemoreceptors rather than pulmonary receptors (Jain
et al. 1972).
We conclude that in human subjects, the noxious
respiratory sensation, decrease in mean arterial pressure
and early respiratory events such as apnoea and cough
associated with an intravenous injection of lobeline
require intact pulmonary afferents. Therefore, we
suggest that the entire period of the noxious sensations
most likely corresponds to a period of stimulation of
pulmonary but not bronchial lobeline-sensitive receptors.
Finally, we have presented some evidence for
reinnervation of pulmonary afferents in subjects who
have undergone bilateral lung transplantation.
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